Interneuron Pharmaceuticals Inc., based in Lexington,Mass., will get a second crack at convincing an FDAadvisory committee to favorably recommend approval ofits anti-obesity drug, dexfenfluramine. (See BioWorldToday, Sept. 19, 1995, p. 1.)
The Endocrinologic and Metabolic Drugs AdvisoryCommittee, which adjourned on Sept. 28, 1995, withouttaking any final action, will meet on Nov. 16, 1995, toresume its discussion of whether the drug should beapproved.
Interneuron Vice President for CorporateCommunications William Boni told BioWorld Today thatnew toxicology data will be presented "to resolve anyconfusion" among the advisory panel members. _Michele L. Robinson
(c) 1997 American Health Consultants. All rights reserved.